Tenofovir disoproxil fumarate associated Fanconi syndrome in an HIV-uninfected man receiving HIV pre-exposure prophylaxis

被引：0
|
作者：
Dube, M. P. [1 ]
Funk, C. A. [1 ]
Corado, K. [2 ]
Morris, S. [3 ]
机构：
[1] Univ Southern Calif, Keck Sch Med, Los Angeles, CA USA
[2] Harbor UCLA Med Ctr, Los Angeles Biomed Res Inst, Los Angeles, CA USA
[3] Univ Calif San Diego, Sch Med, San Diego, CA 92103 USA
来源：
ANTIVIRAL THERAPY | 2016年 / 21卷
关键词：
D O I：
暂无
中图分类号：
R51 [传染病];
学科分类号：
100401 ;
摘要：
A57
引用
收藏
页码：A57 / A57
页数：1
相关论文
共 50 条
  • [21] Pre-exposure prophylaxis (PrEP) in HIV-uninfected individuals with high-risk behaviour
    Nadery, S.
    Geerlings, S. E.
    NETHERLANDS JOURNAL OF MEDICINE, 2013, 71 (06): : 295 - 299
  • [22] TENOFOVIR DISOPROXIL FUMARATE ASSOCIATED FANCONI SYNDROME IN PATIENTS FROM A HIV-ENDOCRINOLOGY CLINIC
    Seow, C. J.
    OSTEOPOROSIS INTERNATIONAL, 2020, 31 (SUPPL 1) : S573 - S573
  • [23] Pre-exposure prophylaxis failure with tenofovir disoproxil
    Streeck, Hendrik
    Verheyen, Jens
    Storim, Julian
    Dittmer, Ulf
    Jochum, Christoph
    Timm, Jrg
    Esser, Stefan
    AIDS, 2017, 31 (01) : 176 - 177
  • [24] Tenofovir Disoproxil Fumarate/Emtricitabine Prophylaxis Has No Effect on Bone Mineral Density and Bone Mineral Content in African Breastfeeding Women Receiving Pre-Exposure Prophylaxis for HIV
    Kistan, Gaysheen
    Sebitloane, Motshedisi
    Lombard, Carl
    Godlwana, Zukiswa
    Desmond, Alicia C.
    Clark, Richard
    Rooney, James F.
    Gray, Glenda
    Moodley, Dhayendre
    JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES, 2025, 98 (03) : 265 - 273
  • [25] HIV-1 Evolution in Breakthrough Infections in a Human Trial of Oral Pre-exposure Prophylaxis With Emtricitabine and Tenofovir Disoproxil Fumarate
    Ruone, Susan
    Paxton, Lynn
    McLaurin, Tony
    Taylor, Allan
    Hanson, Debra
    Heneine, Walid
    Brooks, John T.
    Garcia-Lerma, Jose Gerardo
    JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES, 2016, 72 (02) : 129 - 132
  • [26] In utero exposure to tenofovir disoproxil fumarate does not impair growth and bone health in HIV-uninfected children born to HIV-infected mothers
    Vigano, Alessandra
    Mora, Stefano
    Giacomet, Vania
    Stucchi, Sara
    Manfredini, Valeria
    Gabiano, Clara
    Salvini, Filippo
    Cellini, Monica
    Tamburrini, Enrica
    Puzzovio, Maria
    Zuccotti, Gian Vincenzo
    ANTIVIRAL THERAPY, 2011, 16 (08) : 1259 - 1266
  • [27] Tenofovir-based HIV pre-exposure prophylaxis
    Paxton, Lynn A.
    FUTURE VIROLOGY, 2013, 8 (12) : 1207 - 1218
  • [28] Changes in renal function associated with oral emtricitabine/tenofovir disoproxil fumarate use for HIV pre- exposure prophylaxis
    Solomon, Marc M.
    Lama, Javier R.
    Glidden, David V.
    Mulligan, Kathleen
    McMahan, Vanessa
    Liu, Albert Y.
    Vicente Guanira, Juan
    Veloso, Valdilea G.
    Mayer, Kenneth H.
    Chariyalertsak, Suwat
    Schechter, Mauro
    Bekker, Linda-Gail
    Kallas, Esper Georges
    Burns, David N.
    Grant, Robert M.
    AIDS, 2014, 28 (06) : 851 - 859
  • [29] Daily HIV pre-exposure prophylaxis (PrEP) with tenofovir disoproxil fumarate-emtricitabine reduced Streptococcus and increased Erysipelotrichaceae in rectal microbiota
    Dube, Michael P.
    Park, Sung Yong
    Ross, Heather
    Love, Tanzy M. T.
    Morris, Sheldon R.
    Lee, Ha Youn
    SCIENTIFIC REPORTS, 2018, 8
  • [30] Fanconi syndrome due to tenofovir disoproxil fumarate reversed by switching to tenofovir alafenamide fumarate in an HIV-infected patient
    Mothobi, Nomvuyo Z.
    Masters, Jeffrey
    Marriott, Deborah J.
    THERAPEUTIC ADVANCES IN INFECTIOUS DISEASE, 2018, 5 (05) : 91 - 95
12345